Provide formulations comprising an Antibody anti IL - 1 3, including Pharmaceutical formulations and Methods of use of such formulations. Claim 1: a formulation comprising an Antibody anti IL13, where the concentration of Antibody in the formulation is at least 100 mg / ml and the viscosity of the formulation is less than 15 centipoise (CP) at 25oC.Claim 2: the formulation according to claim 1, wherein the IL13 Antibody comprises three regions of heavy chain CDR H1, where has the amino acid sequence of SEQ ID no. 1 Cor - H2 has the amino acid sequence of SEQ ID no. 2 and CDR H3 has the sequence of ami No u00e1cidos of SEQ ID no. 3 and Three light chain CDR,Where cor - L1 has the amino acid sequence of SEQ ID no. 4, CDR L2 has the amino acid sequence of SEQ ID no. 5 and cor - L3 has the amino acid sequence of SEQ ID no. 6. Claim 1: the formulation according to claim 1 which comprises histidine acetate buffer of pH 5.4, 6.0, where the concentration of histidine in the acetate buffer is between 5 mm and 40 mm.Claim 12: Formulation according to claim 11, which also includes a polyol and a Surfactant, where the concentration of polyol formulation is between 100 mm and 200 mm and the concentration of the Surfactant in the formulation is between 0.01% and 0.1%.Claim 13: Formulation according to claim 12, wherein the polyol and the Surfactant is is sucrose Polysorbate 20.Se proporcionan formulaciones que comprenden un anticuerpo anti-IL-1 3, incluyendo formulaciones farmacéuticas y métodos de uso de dichas formulaciones. Reivindicación 1: Una formulación que comprende un anticuerpo anti-IL13, en donde la concentración de anticuerpo en la formulación es de al menos 100 mg/mL y la viscosidad de la formulación es inferior a 15 centipoise (cP) a 25ºC. Reivindicación 2: La formulación de acuerdo con la reivindicación 1, en donde el anticuerpo anti-IL13 comprende tres CDR de cadena pesada, donde CDR-H1 tiene la secuencia de aminoácidos de SEQ ID Nº 1, CDR-H2 tiene la secuencia d
